Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
Chapter Links... |
Cancer Drug Fund List |
Northern Cancer Alliance |
Northern England Clinical Networks Palliative and End of Life Care Guidelines |
Details... |
08.01.05 |
Other antineoplastic drugs |
|
|
Acalabrutinib (Calquence®)
|
Formulary
|
- 100mg capsules
- Approved for treating chronic lymphocytic leukaemia in adults in line with NICE
|
NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
|
Aflibercept (Zaltrap®)
|
Formulary
|
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
MHRA Drug Safety Update (April 2016): Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Alectinib (Alecensa®)
|
Formulary
|
- 150mg capsules
- Approved as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults in line with NICE
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
|
Asciminib (Scemblix®)
|
Formulary
|
- 20mg and 40mg tablets
- Approved as an option for treating chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia without a T315I mutation after 2 or more tyrosine kinase inhibitors in adults, in line with NICE
|
NICE TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
|
Atezolizumab
|
Formulary
|
- 840mg/14ml & 1200mg/20m concentrate for solution for infusion (IV)
- 1875mg/15ml solution for injection (S/C)
- Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour).
- Approved in combination with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE
- Approved for the treatment of advanced non-small-cell lung cancer in line with NICE
- Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
- Approved for for adjuvant treatment of resected non-small-cell lung cancer in adults in line with NICE
- Approved with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults in line with NICE
- Approved with nab‑paclitaxel for triple-negative, unresectable, PD‑L1‑positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
- Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
MHRA Drug Safety Update (June 2021): Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
|
Axicabtagene ciloleucel
|
Formulary
|
- 0.4 – 2 × 108 cells dispersion for infusion
|
NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
|
Brexucabtagene autoleucel (Tecartus®)
|
Formulary
|
- 0.4 – 2 × 108 cells dispersion for infusion
|
NICE TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
|
Carfilzomib (Kyprolis®)
|
Formulary
|
- Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
- Approved in combination with dexamethasone and lenalidomide for previously treated multiple myeloma in line with NICE
|
NICE TA657: Carfilzomib for previously treated multiple myeloma (COVID-19)
NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
MHRA Drug Safety Update (Aug 2019): Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
MHRA Drug Safety Update (Dec 2019): Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
|
Cemiplimab (Libtayo®)
|
Formulary
|
- Approved for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults in line with NICE
|
NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma
|
Chlormethine Gel
|
Formulary
|
160 micrograms/g gel
Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:
• Overview | Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | Guidance | NICE
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.
|
|
Crisantaspase (Erwinase)
|
Formulary
|
|
|
Dacomitinib (Vizimpro®)
|
Formulary
|
- Approved as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults in line with NICE
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Daratumumab (Darzalex®)
|
Formulary
|
- Approved in combination with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable in line with NICE
- Approved as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment in line with NICE
- Approved with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable in line with NICE and NHSE Specialised Commissioning guidance
- Approved in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis in line with NICE and NHSE Specialised Commissioning Guidance
|
NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
MHRA Drug Safety Update (Aug 2019): Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus
|
Dinutuximab beta (Qarziba®)
|
Formulary
|
- 20mg/4.5mL concentrate for solution for infusion
- Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE
|
NICE TA 538: Dinutuximab beta for treating neuroblastoma
|
Dostarlimab (Jemperli)
|
Formulary
|
- 500mg/10ml concentrate for solution for infusion
- Approved for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy in line with NICE
- Approved with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE
|
NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA963: Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
|
Durvalumab (Imfinzi®)
|
Formulary
|
- Approved for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults in line with NICE.
- Approved in combination with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer in line with NICE and NHS England Specialised Commissioning Policy.
|
NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
|
Entrectinib (Rozlytrek®)
|
Formulary
|
- Approved for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors in line with NICE
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA644 Entrectinib for treating NTRK fusion-positive solid tumours
|
Epcoritamab (Tepkinly®)
|
Formulary
|
- 4mg/0.8ml & 48mg/0.8ml solution for injection
- Approved for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE
|
NICE TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
|
Eribulin (Halaven®)
|
Formulary
|
- Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens in accordance with NICE and NHS England Commissioning Policy
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Fedratinib
|
Formulary
|
|
|
Fostamatinib
|
Formulary
|
100mg and 150mg film-coated tablets
Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:
• NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm
|
NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
|
Gemtuzumab ozogamicin (Mylotarg®)
|
Formulary
|
- Approved for untreated acute myeloid leukaemia in line with NICE
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
|
Gilteritinib (Xospata®)
|
Formulary
|
- Approved for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults in line with NICE
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Glofitamab (Columvi®)
|
Formulary
|
- 2.5mg and 10mg concentrate for solution for infusion
- Approved for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning guidance
|
NICE TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
|
Idelalisib
|
Formulary
|
- Approved in combination with rituximab for the treatment of:
- Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
- Chronic lympocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months NICE.
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
MHRA Drug Safety Update (May 2016): Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials.
MHRA Drug Safety Update (September 2016): Idelalisib (Zydelig▼): updated indications and advice on minimising the risk of infection
|
Imlifidase (Idefirix®)
|
Formulary
|
- 11mg powder for concentrate for solution for infusion
- Approved for desensitisation treatment before kidney transplant in people with chronic kidney disease in line with NICE and NHSE Commissioning Policy
|
NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
|
Inotuzumab ozogamicin (Besponsa®)
|
Formulary
|
- Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Isatuximab
|
Formulary
|
20mg/mL concentrate for solution for infusion.
Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:
• NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Not approved in accordance with the following NICE TAs:
• NICE TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
|
Ivosidenib (Tibsovo®)
|
Formulary
|
- 250mg tablets
- Approved for for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy.
|
NICE TA948: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
|
Ixazomib
|
Formulary
|
- Capsules: 2.3mg, 3mg, 4mg
|
NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
|
Larotrectinib
|
Formulary
|
20 mg/mL oral solution
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
|
Loncastuximab tesirine (Zynlonta®)
|
Formulary
|
- 10mg powder for concentrate for solution for infusion
- Approved or treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy
|
NICE TA947: Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
|
Lorlatinib (Lorviqua®)
|
Formulary
|
- Approved for previously treated ALK-positive advanced non-small-cell lung cancer in adults in line with NICE
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
|
Lutetium (177Lu)
|
Formulary
|
- Lutetium (177Lu) oxodotreotide (Lutathera)
- Approved for treating unresectable or metastatic neuroendocrine tumours in adults in line with NICE
- Lutetium-177 vipivotide tetraxetan (Pluvicto)
- Approved for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults in line with NICE
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
NICE TA930: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
|
Midostaurin (Rydapt®)
|
Formulary
|
- Approved for the treatment of advanced systemic mastocytosis in line with NICE
|
NICE TA523 Midostaurin for untreated acute myeloid leukaemia
NICE TA728: Midostaurin for treating advanced systemic mastocytosis
|
Mogamulizumab (Poteligeo®)
|
Formulary
|
- Approved for previously treated mycosis fungoides and Sézary syndrome in line with NICE
|
NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
|
Momelotinib (Omjjara®)
|
Formulary
|
- 100mg, 150mg and 200mg tablets
- Approved for treating myelofibrosis-related splenomegaly or symptoms in adults in line with NICE
|
NICE TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
|
Neratinib (Nerlynx®)
|
Formulary
|
- Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
|
Niraparib (Zejula®)
|
Formulary
|
- Approved for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE
|
MHRA Drug Safety Update (Oct 2020): Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
|
Nivolumab-relatlimab (Opdualag®)
|
Formulary
|
- 240mg/20ml (12mg/1ml) & 80mg/20ml (4mg/1ml) concentrate for solution for infusion
- Approved for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over in line with NICE
|
NICE TA950: Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over
|
Olaparib (Lynparza®)
|
Formulary
|
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
- Approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation in line with NICE
- Approved for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults in line with NICE
- Approved for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults in line with NICE
- Approved as maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults in line with NICE and NHSE Specialised Commissioning policy
- Approved with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE and NHSE Specialised Commissioning policy
- Approved with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults in line with NICE
- Approved for maintenance treatment of BRCA muatation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
|
NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
NICE TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
|
Pablociclib (Ibrance®)
|
Formulary
|
|
|
Panobinostat
|
Formulary
|
- Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pembrolizumab (Keytruda®)
|
Formulary
|
- Approved for the treatment of advanced melanoma after disease progression with ipilimumab in accordance with NICE.
- Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE.
- Approved for treating PD-L1-positive non-small-cell lung cancer
- Approved for treating PD-L1-positive metastatic non-small-cell lung cancer
- Approved for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more in line with NICE
- Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
- Approved for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults in line with NICE
- Approved for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
- Approved with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults in line with NICE
- Approved for adjuvant treatment of completely resected stage 3 melanoma in line with NICE
- Approved in combination with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer in line with NICE
- Approved for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies in line with NICE
- Approved with paclitaxel or nab‑paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
- Approved for adjuvant treatment of renal cell carcinoma in adults in line with NICE
- Approved for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over in line with NICE
- Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations in line with NICE
- Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults in line with NICE
- Approved with lenvatinib for previously treated advanced or recurrent endometrial cancer in line with NICE and NHSE Specialised Commissioning guidance
- Approved for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE and NHSE Specialised Commissioning guidance
- Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in line with NICE
- Approved for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over in line with NICE
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma
NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over
MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
|
Polatuzumab vedotin (Polivy®)
|
Formulary
|
- Approved with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant in line with NICE
- Approved with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults - in line with NICE TA874.
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
|
Pomalidomide
|
Formulary
|
Commissioner: NHS England
Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
|
Ramucirumab (Cyramza®)
|
Formulary
|
|
NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Rucaparib
|
Formulary
|
|
MHRA Drug Safety Update (Sep 2022) Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
|
Sacituzumab govitecan (Trodelvy®)
|
Formulary
|
- 180mg powder for solution for infusion
|
NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
|
Selinexor (Nexpovio®)
|
Formulary
|
- 20mg tablets
- Approved with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults in line with NICE
- Approved with bortezomib and dexamethasone for previously treated multiple myeloma in adults in line with NICE
|
NICE TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
NICE TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma
|
Selpercatinib
|
Formulary
|
- 40mg and 80mg capsules
- Approved for advanced thyroid cancer with RET alterations in people 12 years and older in line with NICE
- Approved for untreated RET fusion-positive advanced non-small-cell lung cancer in adults in line with NICE
|
NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations
NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
|
Selumetinib (Koselugo®)
|
Formulary
|
- 10mg and 35mg hard capsules
- Approved treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over in line with NICE
|
NICE HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
|
Sotorasib (Lumykras)
|
Formulary
|
|
|
Talazoparib (Talzenna®)
|
Formulary
|
- 0.25mg and 1mg capsule
- Approved or HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults in line with NICE
|
NICE TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
|
Talimogene laherparepvec
|
Formulary
|
- Approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy (SSC1679).
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
|
Tisagenlecleucel
|
Formulary
|
- Approved for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under in line with NICE
|
NICE TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under
|
Tivozanib (Fotivda®)
|
Formulary
|
- Capsules: 890 mg and 1340 mg
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
MHRA Drug Safety Updates (July 2020) Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Trastuzumab deruxtecan (Enhertu)
|
Formulary
|
Vial: powder for concentrate for infusion, 100 mg
|
NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
NICE TA862: HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
|
Venetoclax (Venclyxto®)
|
Formulary
|
- Approved in combination with rituximab for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy in line with NICE
- Approved in combination with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable in line with NICE
- Approved in combination with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable in line with NICE.
- Approved for the treatment of chronic lymphocytic leukaemia in adults:
- with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
- without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor in line with NICE
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia
MHRA Drug Safety Update (Dec 2021): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)
|
Zanabrutinib (Brukinsa)
|
Formulary
|
- 80mg capsule
- Approved for the treatment of chronic lymphocytic leukaemia in line with NICE and NHSE Specialised Commissioning guidance
|
NICE TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
|
Picibanil
|
Unlicensed
|
|
|
Streptozocin
|
Unlicensed
|
- Named patient supply only.
|
|
08.01.05 |
Amsacrine |
|
|
Amsacrine
|
Formulary
|
|
|
08.01.05 |
CDK inhibitors |
|
|
08.01.05 |
Arsenic trioxide |
|
|
Arsenic Trioxide
|
Formulary
|
- NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL).
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
08.01.05 |
Bevacizumab |
|
|
Bevacizumab (Avastin®)
|
Formulary
|
|
NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
08.01.05 |
Bexarotene |
|
|
Bexarotene (Targretin®)
|
Formulary
|
|
|
08.01.05 |
Bortezomib |
|
|
Bortezomib
|
Formulary
|
- Approved for:
- Relapsed multiple myeloma in line with in line with NICE.
- Combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE.
- Induction therapy for multiple myeloma in line with NICE.
- Treatment of adults with mantle cell lymphoma that has not been treated before, if haemotopoietic stem cell transplantation is not suitable, in line with NICE.
|
NICE TA129: Multiple myeloma - bortezomib
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
|
08.01.05 |
Brentuximab vedotin |
|
|
Brentuximab vedotin (Adcetris®)
|
Formulary
|
- 50mg powder for concentrate for solution for infusion
- Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
- Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
- if they have already had autologous stem cell transplant
- if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable.
- Approved for the treatment of CD30-positive cutaneous T-cell lymphoma in line with NICE
- Approved in combination with cyclophosphamide, doxorubicin and prednisone for untreated systmic anaplastic large cell lymphoma in adults in line with NICE
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
08.01.05 |
Cetuximab |
|
|
Cetuximab
|
Formulary
|
- Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy - as per NICE).
- NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan.
- Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE.
- Approved for previously untreated metastatic colorectal cancer in line with NICE.
- Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
- Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity)
MHRA Drug Safety Update (Feb 2014): Cetuximab: new safety information available
MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
|
08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
|
Formulary
|
|
|
Temozolomide
|
Formulary
|
- Approved for the treatment of recurrent malignant glioma in line with NICE.
- Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
|
NICE TA121: Glioma (newly diagnosed and high grade)
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
08.01.05 |
Erlotinib |
|
|
Erlotinib
|
Formulary
|
- Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
- Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
- Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Roche Healthcare Professional Letter (January 2016): Tarceva (erlotinib)
MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
|
08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
|
Formulary
|
- 100mg tablets
- 500mg capsules
- 500mg in 5ml suspension (unlicensed) is also approved
- When used to treat non-malignant conditions in accordance with shared care protocol
|
|
08.01.05 |
Imatinab |
|
|
08.01.05 |
Ipilimumab |
|
|
Ipilimumab (Yervoy®)
|
Formulary
|
- Approved for previously treated advanced melanoma in line with NICE.
- Approved for previously untreated advanced melanoma in line with NICE.
- Approved in combination with nivolumab for untreated renal cell carcinoma in line with NICE.
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
|
08.01.05 |
Mitotane |
|
|
Mitotane
|
Formulary
|
|
|
08.01.05 |
Panitumumab |
|
|
Panitumumab (Vectibix®)
|
Formulary
|
- Approved for previously untreated metastatic colorectal cancer in line with NICE.
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
MHRA Drug Safety Update (May 2010): Panitumumab (Vectibix): serious hypersensitivity reactions
MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
MHRA Drug Safety Update (September 2012): Panitumumab (Vectibix): risk of necrotising fasciitis
MHRA Drug Safety Update (September 2013): Panitumumab: treatment of metastatic colorectal cancer
|
08.01.05 |
Pentostatin |
|
|
Pentostatin (Nipent®)
|
Formulary
|
|
|
08.01.05 |
Platinum compounds |
|
|
Carboplatin
|
Formulary
|
|
|
Cisplatin
|
Formulary
|
|
|
Oxaliplatin
|
Formulary
|
- Approved for Dukes C colon cancer in combination with 5-fluorouracil
and folinic acid in line with NICE.
- Approved for advanced and metastatic colorectal cancer in line with NICE.
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
|
08.01.05 |
Porfimer sodium and temoporfin |
|
|
Porfimer Sodium (Photofrin ®)
|
Formulary
|
|
|
08.01.05 |
Procarbazine |
|
|
Procarbazine
|
Formulary
|
|
|
08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
|
Formulary
|
- Approved as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and they have not had an EGFR-TK inhibitor before NICE and additional NHS England criteria.
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Axitinib (Inlyta®)
|
Formulary
|
- Approved as treatment for adults with advanced renal cell carcinoma when tyrosine kinase inhibitors or cytokines have not worked in line with NICE.
|
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Bosutinib (Bosulif®)
|
Formulary
|
- Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatanib are not appropriate in line with NICE.
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
|
Brigatinib (Alunbrig®)
|
Formulary
|
- Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE.
- Approved for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in line with NICE
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
|
Cabozantinib (Cometriq®)
|
Formulary
|
- Approved for use in the treatment of renal cell carcinoma in line with NICE and NHS England Commissioning Policy
- Approved for the treatment of medullary thyroid cancer in line with NICE and NHS England Commissioning Policy
- Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy
- Approved with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults in line with NICE
|
NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516: Cabozantinib for treating medullary thyroid cancer
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
NICE TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma
NICE TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Ceritinib
|
Formulary
|
- Approved for use in previously treated anaplastic lymphoma kinase positive non-small-cell-lung cancer in line with NICE and NHS England Commissioning Policy.
- Approved for untreated ALK-positive non-small-cell lung cancer in line with NICE and NHS England Commissioning Policy
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Crizotinib
|
Formulary
|
- Approved in accordance with NICE and NHS England Commissioning Policy.
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
MHRA Drug Safety Update (Nov 2015): Crizotinib (Xalkori▼): risk of cardiac failure
|
Dasatinib (Sprycel®)
|
Formulary
|
- Approved for use in accordance with NICE and NHS EnglandCommissioning Policy
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
|
Encorafenib (Braftovi®)
|
Formulary
|
- Approved in combination with binimetinib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults in line with NICE
- Approved in combination with cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
|
Everolimus (Afinitor®, Votubia®)
|
Formulary
|
- 2.5mg, 5mg & 10mg tablets (Votubia®)
- Approved for the treatment of angiomyolipomas associated with tuberous sclerosis in accordnace with NHS England Commissioning Policy.
- Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy.
- 5mg & 10mg tablets (Afinitor®)
- Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE.
- Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
- Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE.
- Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
|
Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
NICE TA348: Everolimus for preventing organ rejection in liver transplantation
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA481: Immunosuppressive therapy for kidney transplant in adults
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Gefitinib
|
Formulary
|
- Approved for first line use in locally advanced or metastatic NSCLC in line with NICE.
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
|
Ibrutinib (Imbruvica®)
|
Formulary
|
- Approved for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in line with NICE and NHS Commissioning Policy.
- Approved for treating relapsed or refractory mantle cell lymphoma in line with NICE and NHS England Commissioning Policy if:
- they have had only 1 previous line of therapy
- Approved for untreated chronic lymphocytic leukaemia in line with NICE
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA795: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
MHRA Drug Safety Update (August 2017): Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
|
Imatinib
|
Formulary
|
- Approved for the first-line management of people with KIT (CD117)- positive unresectable and/or KIT (CD117)-positive metastatic gastrointestinal stromal tumours (GISTs) in line with NICE.
- Approved for the adjuvant treatment of gastrointestinal stromal tumours (GISTs) after surgery when there is a high risk relapse of tumour NICE.
- Approved for Philadelphia-chromosome-positive CML in the accelerated phase or with blast crisis in line with NICE.
- A standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosomepositive CML in line with NICE.
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
|
Lapatinib (Tyverb®)
|
Formulary
|
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
|
Lenvatinib (Kisplyx®)
|
Formulary
|
- 4mg & 10mg capsules
- Approved with everolimus for previously treated advanced renal cell carcinoma in line with NICE
- Approved to the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE
- Approved for untreated advanced hepatocellular carcinoma in line with NICE
|
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Mobocertinib
|
Formulary
|
|
NICE TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
|
Nilotinib (Tasigna®)
|
Formulary
|
- Approved for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML in line with NICE and NHS Commissioning Policy
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
|
Nintedanib
|
Formulary
|
- Approved for the treatment of locally advanced, metastatic or locally recurrent non-small-cell lung cancer who have previously been treated been with first-line chemotherapy in accordance with NICE.
- Approved for treating idiopathic pumonary fibrosis in line with NICE
|
NICE TA347: Recurrent non-small-cell lung cancer
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
NICE TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Pazopanib (Votrient®)
|
Formulary
|
- Approved for advanced renal cell carcinoma in line with NICE
|
NICE TA215: Pazopanib in renal cell cancer
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Pemigatinib (Pemaryze®)
|
Formulary
|
- 4.5mg, 9mg and 13.5mg tablets
- Approved for the treatment of relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in line with NICE
|
NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
|
Ponatinib (Iclusig®)
|
Formulary
|
- 15mg, 30mg & 45mg film-coated tablets
- Approved for the treatment of chronic myeloid leukaemia and acute lymphoblastic leukaemia in line with NICE and NHS England Commissioning Policy
|
NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
MHRA Drug Safety Update (October 2018): Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
MHRA Drug Safety Update (April 2017): Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
|
Regorafenib (Stivarga® )
|
Formulary
|
- 40mg tablets
- Approved for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib in line with NICE and NHS England Commissioning Policy.
- Approved for treating advanced hepatocellular carcinoma in adults who have had sorafenib in line with NICE
- Approved as an option for metastatic colorectal cancer in adults who have had previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are unsuitable - in line with NICE.
|
NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA866: Regorafenib for previously treated metastatic colorectal cancer
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Ruxolitinib
|
Formulary
|
- Approved for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemiaa myelofibrosis, only in people with intermediate-2 or high-risk disease in line with NICE.
- Approved for treating polycythaemia vera in line with NICE and NHSE Specialised Commissioning guidance
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
NICE TA921: Ruxolitinib for treating polycythaemia vera
|
Sorafenib (Nexavar®)
|
Formulary
|
- 200mg tablets
- Approved for treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment in line with NICE and NHS Commissioning Policy.
- Approved for the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE.
- Approved as maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) in line with NHS England Specialised Commissioning Policy
- Only available at The Newcastle upon Tyne Hospitals NHS Trust
|
NHS England Specialised Commissioning Policy: Sorafenib maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT)
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Sunitinib (Sutent®)
|
Formulary
|
- Approved for gastrointestinal stromal tumours (GISTs) in line with NICE.
- Approved for advanced and/or metastatic renal cell carcinoma in line with NICE.
- Sunitinib not approved for second line use in advanced and/or metastatic renal cell carcinoma NICE.
- Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
|
Temsirolimus (Torisel®)
|
Formulary
|
|
|
Trametinib
|
Formulary
|
- Approved in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in line with NICE and NHS England Commissioning Policy.
- Approved for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC) in line with NHSE Specialised Commissioning Policy
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
MHRA Drug Safety Update (March 2016) Trametinib (Mekinist▼): risk of gastrointestinal perforation and colitis
|
Tucatinib (Tukysa®)
|
Formulary
|
- Approved in combination with trastuzumab and capecitabine for HER2‑positive locally advanced or metastatic breast cancer in adults after 2 or more anti‑HER2 treatment therapies in line with NICE
|
NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
|
Vemurafenib
|
Formulary
|
- Approved melanoma (BRAF V600 mutation positive, unresectable metastatic) in line with NICE.
|
NICE TA269: Vemurafenib for treating malignant melanoma
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Zanubrutinib (Brukinsa®)
|
Formulary
|
|
NICE TA833: Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
|
08.01.05 |
Taxanes |
|
|
Cabazitaxel
|
Formulary
|
- Approved for the treatment of hormone relapsed metastatic prostate cancer treated with with docetaxel in line with NICE.
|
MHRA Drug Safety Update (December 2014) Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel
|
Formulary
|
- Approved for early node-positive breast cancer in line with NICE.
- Approved for hormone refractory metastatic prostate cancer in line with NICE.
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
|
Paclitaxel
|
Formulary
|
- The following formulations are approved:
- 30mg in 5ml, 100mg in 16.7ml, and 150mg in 25ml concentrate for preparing IV infusion.
- Approved for the treatment of recurrent ovarian cancer in line with NICE.
|
MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
|
Paclitaxel - Albumin Bound Formulation (Abraxane®)
|
Formulary
|
- Note: Abraxane® 5mg in 1ml powder for suspension for infusion is restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.
- Approved in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) for first line therapy in ovarian cancer in line with NICE.
- Approved in combination with a platinum-based drug (carboplatin or cisplatin) for second-line (or subsequent) therapy in ovarian cancer in line with NICE
- Approved metastatic breast cancer in line with NICE.
- Abraxane is not recommended for the adjuvant treatment of women with early node-positive breast cancer NICE.
- Approved in combination with gemcitabine for untreated metastatic pancreatic cancer in line with NICE and NHS England Commissioning Policy as of 5th December 2017
|
NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
|
08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan Hydrochloride
|
Formulary
|
|
|
Topotecan
|
Formulary
|
- Approved for relapsed NSCLC in line with NICE.
- Approved for recurrent or stage IVB cervical cancer in line with NICE.
- Approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE.
- Approved for the treatment of recurrent ovarian cancer in line with NICE.
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
08.01.05 |
Trabectedin |
|
|
Trabectedin
|
Formulary
|
Approved for the treatment of recurrent ovarian cancer in line with NICE.
|
NICE TA185: Soft tissue sarcoma - trabectedin
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
08.01.05 |
Trastuzumab |
|
|
Pertuzumab (Perjeta®)
|
Formulary
|
- Approved for the neoadjuvant treatment of HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
- Approved with trastuzumab and docetaxel for treating HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
- Approved for adjuvant treatment of HER2-positive early stage breast cancer in line with NICE
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Trastuzumab
|
Formulary
|
- Approved for metastatic or locally advanced inoperable gastric cancers in line with NICE.
- Approved for early stage HER2-positive breast cancer in line with NICE.
- Approved for advanced HER2-positive breast cancer in line with NICE.
- Note: trastuzumab is not recommended in combination with an aromatase inhibitor for the first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses HER2 - in line with NICE.
- Trastuzumab 600mg subcutaneous injection is approved by NHS England for HER2-positive breast cancer in line with NECN guidance.
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
NICE TA34: Breast cancer - trastuzumab
|
Trastuzumab emtansine (Kadcyla®) (S/C injection)
|
Formulary
|
- 100mg & 160mg powder for concentrate for solution for infusion
- Approved for the treatment of HER2-positive advanced breast cancer after trastuzumab and a taxane in line with NICE and NHS England Commissioning Policy
- Approved for human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy in line with NICE
|
NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
|
08.01.05 |
Tretinoin |
|
|
Tretinoin
|
Formulary
|
|
|
08.01.05 |
Vismodegib |
|
|
.... |
Non Formulary Items |
Idecabtagene vicleucel
|
Non Formulary
|
- Treating relapsed and frefractory multuiple myeloma after 3 or more treatments
|
NICE TA936: Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)
|
Tisagenlecleucel
|
Non Formulary
|
- Treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies.
|
NICE TA933: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
|
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |
|
Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment.
In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.
For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing. |
|
Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement.
The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber.
If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care. |
|
Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs. |
|
Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care. |
|
NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria. |
|
UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review. |
|
NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status. |
|
|
|